At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 234 enrolled
Drug / intervention
Etrasimod +1 moredrug
Likely dose
Etrasimod 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Etrasimod and Placebo for Ulcerative Colitis. Completed, enrolled 234 participants across 288 sites in 18 countries.
Detailed Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Belarus, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Poland, Portugal, Russia, South Korea, Spain, Ukraine, United States
CollaboratorsArena is a wholly owned subsidiary of Pfizer
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartApr 2021
Primary CompletionJun 2024
TodayJul 2026
First PostedOct 29, 2020
Enrollment StartApr 12, 2021
Primary CompletionJun 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.7 years ago
Interventions
Etrasimoddrug
Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Placebodrug
Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment